Will scale up bio-informatics services: Celestial Labs

Excerpts from Midcap Radar on CNBC-TV18 Watch the full show » RELATED NEWS Stocks in news: Abhishek Mills, Berger Paints, Sadbhav Eng Vivimed Labs close to buying European firm Divis Laboratories hits new high Ipca Labs touches all time high Numbers boosted by API business: Matrix Labs Nifty BSE | NSE 25/05/12 Are Mutual Funds betting on Nifty?

Aditya Narayan Singh , CFO , Celestial Labs , said the company is going to scale up its services in the bio-informatics area. He added the company is also planning to set up a facility for producing industrial enzyme s.

The company is also planning to launch a product - Cell Suite .

Excerpts from CNBC-TV18's exclusive interview with Aditya Narayan Singh:

Q1: Can you take us through the main business lines of the company and what are your plans to do with the money that you raise?

A: We are basically working in the bio-informatics area and would like to scale up our services in that area. We also wanted to set up a facility for producing industrial enzymes and take up drug molecule development, which is in the existing line of business.

Q2: Give us more details about your business, what sort of EPS and balance sheet did you clock the previous quarter?

A: Last year, we did a Rs 14 crore turnover and the profit after tax was at Rs 5.25 crore. We have an EPS of Rs 8.25.

Q3: We understand that you are going to be licensing a product called Cell Suite. Can you take us through when you are expecting this licensing?

A: We have started that process. In fact, we are first using Cell Suite ourselves to create the drug molecule. We are in the process of licensing Cell Suite in the next two to three months.

Q4: And, what kind of revenue upsides can that product bring to you?

A: Cell Suite has been priced at USD 18,000 per user license, which is against the price of about one-third of the cost of the imported tool.